

4-28-2021

Hypertension as a sequela in patients of SARS-CoV-2 infection.

Ganxiao Chen

Department of Cardiology & Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan, China

Xun Li

Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China

Zuojiong Gong

Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China

Hao Xia

Department of Cardiology & Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan, China

Yao Wang

Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China

Follow this and additional works at: <https://jdc.jefferson.edu/medfp>



Part of the [Cardiology Commons](#), and the [Infectious Disease Commons](#)

[See next page for additional authors](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Chen, Ganxiao; Li, Xun; Gong, Zuojiong; Xia, Hao; Wang, Yao; Wang, Xuefen; Huang, Yan; Barajas-Martinez, Hector; and Hu, Dan, "Hypertension as a sequela in patients of SARS-CoV-2 infection." (2021). *Department of Medicine Faculty Papers*. Paper 294.

<https://jdc.jefferson.edu/medfp/294>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Ganxiao Chen, Xun Li, Zuojiang Gong, Hao Xia, Yao Wang, Xuefen Wang, Yan Huang, Hector Barajas-Martinez, and Dan Hu

RESEARCH ARTICLE


Hypertension as a sequela in patients of SARS-CoV-2 infection

Ganxiao Chen^{1‡}, Xun Li^{2‡}, Zuojiang Gong², Hao Xia¹, Yao Wang², Xuefen Wang³, Yan Huang¹, Hector Barajas-Martinez⁴, Dan Hu^{1*}

1 Department of Cardiology & Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan, China, **2** Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China, **3** Nursing department, Renmin Hospital of Wuhan University, Wuhan, China, **4** Lankenau Institute for Medical Research, and Lankenau Heart Institute, Wynnewood, Pennsylvania and Jefferson Medical College, Philadelphia, Pennsylvania, United States of America

‡ These authors share first authorship on this work.

* hdan0716@hotmail.com, rm002646@whu.edu.cn



Abstract

OPEN ACCESS

Citation: Chen G, Li X, Gong Z, Xia H, Wang Y, Wang X, et al. (2021) Hypertension as a sequela in patients of SARS-CoV-2 infection. PLoS ONE 16(4): e0250815. <https://doi.org/10.1371/journal.pone.0250815>

Editor: Bhagwan Dass, University of Florida, UNITED STATES

Received: January 25, 2021

Accepted: April 14, 2021

Published: April 28, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0250815>

Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data cannot be shared publicly because of the contents including information that could compromise research participant privacy/consent. Data are available from the Renmin Hospital of Wuhan University Ethics

Background

COVID-19 is a respiratory infectious disease caused by SARS-CoV-2, and cardiovascular damage is commonly observed in affected patients. We sought to investigate the effect of SARS-CoV-2 infection on cardiac injury and hypertension during the current coronavirus pandemic.

Study design and methods

The clinical data of 366 hospitalized COVID-19-confirmed patients were analyzed. The clinical signs and laboratory findings were extracted from electronic medical records. Two independent, experienced clinicians reviewed and analyzed the data.

Results

Cardiac injury was found in 11.19% (30/268) of enrolled patients. 93.33% (28/30) of cardiac injury cases were in the severe group. The laboratory findings indicated that white blood cells, neutrophils, procalcitonin, C-reactive protein, lactate, and lactic dehydrogenase were positively associated with cardiac injury marker. Compared with healthy controls, the 190 patients without prior hypertension have higher AngII level, of which 16 (8.42%) patients had a rise in blood pressure to the diagnostic criteria of hypertension during hospitalization, with a significantly increased level of the cTnI, procalcitonin, angiotensin-II (AngII) than those normal blood pressure ones. Multivariate analysis indicated that elevated age, cTnI, the history of hypertension, and diabetes were independent predictors for illness severity. The predictive model, based on the four parameters and gender, has a good ability to identify the clinical severity of COVID-19 in hospitalized patients (area under the curve: 0.932, sensitivity: 98.67%, specificity: 75.68%).

Committee (contact via whdxrmyy@126.com) for researchers who meet the criteria for access to confidential data.

Funding: The current work was supported by the National Natural Science Foundation Project of China (Grant No. 81670304, D.H.).

Competing interests: The authors report no relationships that could be construed as a conflict of interest.

Abbreviations: ACE2, angiotensin converting enzyme II; Ang II, Angiotensin II; AT1R, Angiotensin II type-1 receptor; COVID-19, coronavirus disease 2019; cTnI, cardiac troponin I; MERS, middle east respiratory syndrome; RAS, renin-angiotensin system; SARS, severe acute respiratory syndrome.

Conclusion

Hypertension, sometimes accompanied by elevated cTnI, may occur in COVID-19 patients and become a sequela. Enhancing Ang II signaling, driven by SARS-CoV-2 infection, might play an important role in the renin-angiotensin system, and consequently lead to the development of hypertension in COVID-19.

Introduction

In December 2019, an acute respiratory infectious disease known as "coronavirus disease 2019 (COVID-19)" caused by a novel coronavirus occurred in Wuhan, China [1, 2]. Whole-genome sequencing and systematic analysis showed that this novel coronavirus is a distinct clade from beta coronavirus associated with human severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [3], and was now officially named "SARS-CoV-2" by World Health Organization. Both SARS-CoV and SARS-CoV-2 have been identified to use the angiotensin converting enzyme II (ACE2) receptor as the portal of entry into the affected cell [4, 5]. ACE2, a membrane-bound aminopeptidase, is highly expressed in the heart and lung [6, 7]. Although the main clinical features of COVID-19 are dominated by respiratory symptoms, many patients with severe cardiovascular damage have been reported by our team and others [8, 9]. Besides, patients with underlying cardiovascular diseases might have an increased risk of death [8]. So, understanding the damage to the cardiovascular system caused by SARS-CoV-2 and the underlying mechanisms is of great importance so that these patients can be treated timely, and the mortality can be reduced. In this retrospective cohort study, the clinical data of hospitalized COVID-19-confirmed patients were analyzed to explore the consequences of SARS-CoV-2 infection on the cardiovascular system.

Materials and methods

Study setting and population

There were 366 COVID-19-confirmed patients enrolled in this study, who were hospitalized in the Department of Infectious Diseases, Renmin Hospital of Wuhan University, from February 1 to May 1, 2020. Clinical severity was defined for all enrolled COVID-19 patients according to the guidelines of the National Health Commission of China, including four types as mild, moderate, severe, and critical types [10]. We divided the patients into the non-severe group (mild and moderate types) and the severe group (severe and critical type). Mild type is defined as mild clinical symptoms and no pneumonia manifestation found in imaging. Moderate cases refer to those who present with fever and respiratory tract symptoms, etc. And have pneumonia manifestations found in imaging. Patients considered severe had one of the following three conditions: respiratory distress and respiratory rate higher than 30 times per minute; fingertip blood oxygen saturation less than 93% at rest; partial arterial oxygen pressure (PaO₂) / fraction of inspiration oxygen (FiO₂) less than 300mmHg. Patients in critical type met one of the following criteria: respiratory failure, requiring mechanical ventilation; shock; multiple organ failure, requiring intensive care management. This study was reviewed and approved by the Medical Ethical Committee of Renmin Hospital of Wuhan University. All participants provided written informed consent and agreed to use their medical records for research purposes.

Data collection

The clinical signs and laboratory findings were extracted from electronic medical records (Donghua Hospital Information System). Two independent, experienced clinicians reviewed and abstracted the data. The recorded information includes demographic data, potential comorbidities, symptoms, signs, laboratory test results. The serum level of hypersensitive troponin I (cTnI) exceeding >40 pg/mL was considered cardiac injury [11]. Blood pressures were obtained three fixed times in the morning using standard measurement. History of hypertension was defined as brachial blood pressure $\geq 140/90$ mmHg or self-reported hypertension medication use before hospitalization. For patients without prior hypertension, elevated blood pressure was defined as blood pressure $\geq 140/90$ mmHg more than 3 times during hospitalization.

The processes of patient screening

The screening process for evaluating the effect of SARS-CoV-2 on the cardiovascular system is shown in Fig 1. Serum level of cardiac troponin I (cTnI) was tested in 276 of the 366 patients during hospitalization, among which 8 patients had a history of chronic heart disease (including ischemic heart disease, arrhythmia, valvular disease, and heart failure) and were therefore excluded. Thus, 268 patients were enrolled to evaluate the effect of SARS-CoV-2 on cardiac injury. Of the 366 patients, 278 had complete blood pressure data. Among these, 88 patients had a history of hypertension before hospitalization and were excluded; therefore, 190 patients were grouped to evaluate the effect of SARS-CoV-2 on blood pressure. Among all 366 subjects, 194 subjects had data available on serum level of cTnI and complete blood pressure data. After




Fig 1. The flow diagram of patient screening. Chronic heart disease includes ischemic heart disease, arrhythmia, valvular disease, and heart failure.

<https://doi.org/10.1371/journal.pone.0250815.g001>

the exclusion of the case with a history of chronic heart disease, 186 cases were included to evaluate the association between cTnI, blood pressure, and clinical severity of COVID-19.

Statistical analysis

Student's *t*-test or the Mann-Whitney test was used to compare the mean of continuous variables, Fisher's exact test was used with limited data, the χ^2 test was used to compare the proportion of categorical variables. Spearman correlation analysis was used to analyze the correlation between variables. The logistic regression model was used to determine factors associated with the clinical severity of COVID-19, and the analysis of receiver operating characteristic (ROC) curves was constructed according to standard procedures. The Youden index, defined as (sensitivity + specificity) – 1, was used to derive a reasonable cut-off value. Calibration of the risk prediction model, comparing the observed and predicted probability, was performed via a visual calibration plot in the R program. A P-value of < 0.05 was considered statistically significant. Statistical analysis was carried out using SPSS software version 21.0 and R version 3.0.

Results

The effect of SARS-CoV-2 on cardiac injury

The results showed that the median age of patients with or without cardiac injury was 74 y/o and 49 y/o with statistical significance (median [interquartile range]: 74 [73–86] vs. 49 [40–66] y/o, $p < 0.001$). Males were dominant in the cardiac injury group (86.67%). The cardiac injury was found in 11.19% (30/268) of patients, but 93.33% (28/30) of them were in the severe group. The proportion of cardiac injury was significantly lower in the non-severe group (1.75% vs. 18.18%, $p < 0.001$). Moreover, 66.67% (20/30) of cardiac injury patients in the severe group eventually died. The most frequent symptom of patients was fever, followed by cough, fatigue, dyspnea, and chest stuffiness. The incidences of cough, dyspnea, and chest stuffiness were significantly different between the patients with or without cardiac injury (93.33% vs. 68.91%, $p = 0.005$; 93.33% vs. 38.66%, $p < 0.001$; 86.67% vs. 36.97%, $p < 0.001$; respectively). Hypertension was the most frequent comorbidity, while the incidence of diabetes was significantly different between the two groups (33.33% vs. 14.29%, $p = 0.017$; [Table 1](#)). The laboratory findings indicated that the patients who suffered from cardiac injury had a higher level of white blood cells, neutrophils, monocytes, procalcitonin, C-reactive protein, lactate, and lactic dehydrogenase compared with the patients without cardiac injury (median [interquartile range]: 9.67 [5.62–13.73] vs. 5.93 [4.45–7.06] cells/L, $p < 0.001$; 5.52 [3.83–11.62] vs. 3.72 [2.95–5.47] cells/L, $p < 0.001$; 0.62 [0.42–0.76] vs. 0.44 [0.25–0.69] cells/L, $p = 0.037$; 630 [47.00–2750.00] vs. 60 [32.00–121.00] pg/mL, $p < 0.001$; 81.10 [14.20–142.80] vs. 41.40 [5.00–74.40] mg/L, $p < 0.001$; 2.10 [1.95–3.05] vs. 1.70 [1.15–2.00] mmol/L, $p < 0.001$; 428 [325.00–765.00] vs. 275 [218.00–375.00] U/L, $p < 0.001$; respectively). Correlation analysis showed that white blood cells, neutrophils procalcitonin, C-reactive protein, lactate and lactic dehydrogenase were significantly associated with cTnI, the *r* values were 0.515 [95% CI, 0.394–0.632], 0.486 [95% CI, 0.358–0.591], 0.477 [95% CI, 0.352–0.581], 0.459 [95% CI, 0.338–0.566], 0.424 [95% CI, 0.273–0.559] and 0.438 [95% CI, 0.291–0.561], respectively ([Table 2](#)).

The effect of SARS-CoV-2 on blood pressure

Of the 190 qualified patients, 16 (8.42%) patients had a rise in blood pressure during hospitalization, among which 6 patients were male, and 10 patients were female. As shown in [Table 3](#), no significant differences were found when comparing the baseline demographics, including

Table 1. Clinical characteristics of COVID-19 patients with or without cardiac injury.

	Total	Cardiac injury	
	(n = 268)	Non-injury (n = 238)	Injury (n = 30)
Age (y/o), Median (IQR)	53 (42–69)	49 (40–66)	74 (73–86)* [§]
Gender (n, %)			
Male	144 (53.7)	118 (49.58)	26 (86.67)* [£]
Female	124 (46.3)	120 (50.42)	4 (13.33)* [£]
Clinical categories (n, %)			
Non-severe	114 (42.54)	112 (47.06)	2 (6.67)* [£]
Severe	154 (57.46)	126 (52.94)	28 (93.33)* [£]
Symptoms (n, %)			
Fever	224 (83.58)	196 (82.35)	28 (93.33) [£]
Cough	192 (71.64)	164 (68.91)	28 (93.33)* [£]
Dyspnea	120 (44.78)	92 (38.66)	28 (93.33)* [£]
Chest stuffiness	114 (42.54)	88 (36.97)	26 (86.67)* [£]
Fatigue	148 (55.22)	130 (54.62)	18 (60.00) [£]
Muscle soreness	54 (20.15)	48 (20.17)	6 (20.00) [£]
Comorbidities (n, %)			
Hypertension	94 (35.07)	80 (33.61)	14 (46.67) [£]
Diabetes	44 (16.42)	34 (14.29)	10 (33.33)* [#]
Chronic lung diseases	10 (3.73)	8 (3.36)	2 (6.67) [#]
Chronic kidney diseases	4 (1.49)	2 (0.84)	2 (6.67) [§]
Gastrointestinal diseases	2 (0.75)	2 (0.84)	0 (0)
Malignant tumor	4 (1.49)	0 (0)	4 (13.33)

Student's *t*-test, χ^2 test, and Fisher's exact tests were used to compare the age, gender, clinical category, symptoms, and comorbidities between the two groups ([§] Two-Sample T-test, [£] Pearson's chi-square test, [#] continuous correction Chi-square test, [§] Fisher's exact test).

**P* < 0.05 is considered statistically significant.

<https://doi.org/10.1371/journal.pone.0250815.t001>

age, gender, clinical category, symptoms, and comorbidities between patients with or without elevated blood pressure. Compared with the patients without elevated blood pressure, the level of cTnI and procalcitonin in the 16 patients rose significantly (median [interquartile range]:

Table 2. The laboratory findings of COVID-19 patients with or without cardiac injury.

Laboratory findings	Non-cardiac injury	Cardiac injury	Normal	<i>r</i> values	<i>P</i> -values
	(median, IQR)	(median, IQR)	range		
cTnI (pg/mL)	7.5 (6.00–16.50)	162 (68.20–757.50)*	0–40	1.000	< 0.001
White blood cells ($\times 10^9$ cells/L)	5.93 (4.45–7.06)	9.67 (5.62–13.73)*	3.5–9.5	0.515	< 0.001
Neutrophils ($\times 10^9$ cells/L)	3.72 (2.95–5.47)	5.52 (3.83–11.62)*	1.8–6.3	0.486	< 0.001
Lymphocytes ($\times 10^9$ cells/L)	1.01 (0.59–1.25)	0.67 (0.48–1.39)*	1.1–3.2	-0.230	0.001
Monocytes ($\times 10^9$ cells/L)	0.44 (0.25–0.69)	0.62 (0.42–0.76)*	0.1–0.6	0.127	0.080
Procalcitonin (pg/mL)	60 (32.00–121.00)	630 (47.00–2750.00)*	0–100	0.477	< 0.001
C-reactive protein (mg/L)	41.40 (5.00–74.40)	81.10 (14.20–142.80)*	0–10	0.459	< 0.001
Lactate (mmol/L)	1.70 (1.15–2.00)	2.10 (1.95–3.05)*	0.5–1.5	0.424	< 0.001
Lactic dehydrogenase (U/L)	275 (218.00–375.00)	428 (325.00–765.00)*	120–250	0.438	< 0.001

The Mann-Whitney test was used to compare the differences between non-cardiac injury and cardiac injury groups

**P* < 0.05 is considered statistically significant. Spearman correlation analysis was used to analyze the correlation between the cTnI and other laboratory findings.

<https://doi.org/10.1371/journal.pone.0250815.t002>

Table 3. Clinical characteristics of COVID-19 patients without prior hypertension.

	Total	Blood pressure	
	(n = 190)	Normal (n = 174)	Elevated (n = 16)
Age (y/o), Median (IQR)	54 (39–63)	53 (39–63)	60 (42–70) [§]
Gender (n, %)			
Male	78 (41.05)	72 (41.38)	6 (37.50) [£]
Female	112 (58.95)	102 (58.62)	10 (62.50) [£]
Clinical categories (n, %)			
Non-severe	116 (61.05)	108 (62.07)	8 (50.00) [£]
Severe	74 (38.95)	66 (37.93)	8 (50.00) [£]
Symptoms (n, %)			
Fever	156 (82.11)	142 (81.61)	14 (87.50) [#]
Cough	132 (69.47)	120 (68.97)	12 (75.00) [#]
Dyspnea	70 (36.84)	64 (36.78)	6 (37.50) [£]
Chest stuffiness	68 (35.79)	62 (35.63)	6 (37.50) [£]
Fatigue	96 (50.53)	88 (50.57)	8 (50.00) [£]
Muscle soreness	36 (18.95)	34 (19.54)	2 (12.50) [#]
Comorbidities (n, %)			
Diabetes	28 (14.74)	26 (14.94)	2 (12.50) [#]
Chronic lung diseases	6 (3.16)	6 (3.45)	0 (0)
Gastrointestinal diseases	4 (2.11)	4 (2.30)	0 (0)
Thyroid disease	2 (1.05)	2 (1.15)	0 (0)
Prostate disease	2 (1.05)	2 (1.15)	0 (0)

Student's *t*-test, χ^2 test, and Fisher's exact tests were used to compare the age, gender, clinical category, symptoms, and comorbidities between the two groups ([§] Two-Sample T-test, [£] Pearson's chi-square test, [#] continuous correction Chi-square test). No significant differences were found.

<https://doi.org/10.1371/journal.pone.0250815.t003>

22.00 [18.20–30.00] vs. 3.86 [2.49–5.15], $p < 0.001$; 82 [53–430] vs. 49 [28–73], $p = 0.023$; **Table 4**). Elevated systolic blood pressure was observed in most of the patients, while diastolic blood pressure was in the normal range. The median values of blood pressure and plasma cTnI levels changes of the 16 patients are shown in **Fig 2A**. Systolic blood pressure and cTnI

Table 4. The laboratory findings of patients with or without elevated blood pressure.

Laboratory findings	Normal blood pressure	Elevated blood pressure	Normal range
	(median, IQR)	(median, IQR)	
cTnI (pg/mL)	3.86 (2.49–5.15)	22.00 (18.20–30.00)*	0–40.00
White blood cells ($\times 10^9$ cells/L)	5.24 (3.87–7.00)	4.86 (3.96–6.60)	3.50–9.50
Neutrophils ($\times 10^9$ cells/L)	3.14 (2.48–4.96)	3.64 (3.06–4.94)	1.80–6.30
Lymphocytes ($\times 10^9$ cells/L)	1.13 (0.76–1.56)	0.93 (0.57–1.23)*	1.10–3.20
Monocytes ($\times 10^9$ cells/L)	0.44 (0.33–0.56)	0.55 (0.25–0.61)	0.10–0.60
Hemoglobin (g/L)	128 (118–136)	118 (107–137)	115–150
Procalcitonin (pg/mL)	49 (28–73)	82 (53–430)*	0–100
C-reactive protein (mg/L)	20.00 (2.40–44.50)	7.80 (3.51–33.20)	0–10.00
Lactic dehydrogenase (U/L)	259 (206–313)	259 (208–289)	120–250

The Mann-Whitney test was used to compare the differences between non-hypertension and hypertension groups

* $P < 0.05$ is considered statistically significant.

<https://doi.org/10.1371/journal.pone.0250815.t004>




Fig 2. A. The systolic blood pressure and cTnI change of patients with elevated blood pressure. B. The systolic blood pressure, cTnI, white blood cells, and chest computed tomography changes of one patient with elevated blood pressure. Late follow-up: The 4th week after discharge from the hospital.

<https://doi.org/10.1371/journal.pone.0250815.g002>

levels had a similar trend with the treatment time. In addition, the blood pressure, cTnI, and white blood cells were continuously monitored in one index case (**Fig 2B**). With effective treatment, the patient's condition improved with regards to symptoms and as evident on chest CT. Meanwhile, the systolic blood pressure and white blood cells reverted to the normal range, and the concentrations of cTnI were also gradually decreased. Among the 190 patients without prior hypertension, the serum levels of components in the renin-angiotensin system, including adrenocorticotrophic hormone, renin, angiotensin II (Ang II), and aldosterone, were detected in 28 patients. Comparison with healthy controls showed that AngII were significantly elevated in both the normal and elevated blood pressure groups (median [interquartile range]: 137.12 [123.63–161.67] vs. 87.90 [48.23–107.39] pg/mL, $p < 0.001$; 169.25 [142.17–186.98] vs. 87.90 [48.23–107.39] pg/mL, $p < 0.001$; respectively; **Table 5**). When comparing the RAS between the normal and elevated blood pressure groups, Ang II levels were significantly higher in the latter group (median [interquartile range]: 169.25 [142.17–186.98] vs. 137.12 [123.63–161.67] pg/mL, $p = 0.020$; **Table 6**).

The association between cardiac injury, blood pressure, and clinical severity of COVID-19

Results of demographic and laboratory findings between the severe and non-severe group, based on guidelines of the National Health Commission of China, are shown in **Table 7**. Patients in the severe group were significantly older, with a greater proportion of males (median [interquartile range]: 66 [57–76] vs. 42 [33–51] y/o, $p < 0.001$; 60.00% vs. 40.54%, $p = 0.009$; respectively). In addition, the cTnI, white blood cells, neutrophils, procalcitonin, C-reactive protein, and lactic dehydrogenase of the severe group were significantly higher than those of the non-severe group (median [interquartile range]: 7.00 [5.78–27.00] vs. 5.68 [4.62–6.45] pg/mL, $p < 0.001$; 5.98 [4.60–10.00] vs. 5.07 [3.65–6.00] $\times 10^9$ cells/mL, $p = 0.004$; 3.85 [3.02–8.27] vs. 2.67 [2.15–3.92] $\times 10^9$ cells/mL, $p < 0.001$; 67.50 [32.00–288.00] vs. 36.00 [23.00–57.00] pg/mL, $p = 0.005$; 48.55 [7.40–81.50] vs. 6.20 [0.50–28.00] pg/mL, $p < 0.001$; 316.00 [235.00–454.00] vs. 233.50 [187.50–292.00], $p < 0.001$; respectively). In contrast, patients in the severe group had a significantly lower level of lymphocytes median [interquartile range]: 0.78 [0.48–1.29] vs. 1.27 [0.96–1.73], $\times 10^9$ cells/mL, $p < 0.001$). Further univariate analysis revealed that the age, sex, cTnI, white blood cells, neutrophils, lymphocytes, C-reactive

Table 5. The renin-angiotensin system in subjects with and without COVID-19.

Laboratory findings	Healthy control	Normal blood pressure	Elevated blood pressure
	(median, IQR)	(median, IQR)	(median, IQR)
Adrenocorticotrophic hormone (pg/mL)	31.92 (21.6–39.67)	27.55 (21.12–39.56) [§]	33.03 (19.42–40.89) [§]
Renin (pg/mL)	5.31 (3.21–8.75)	6.35 (3.34–7.83) [†]	5.86 (4.41–6.76) [†]
Angiotensin II (pg/mL)	87.90 (48.23–107.39)	137.12. (123.63–161.67) ^{*†}	169.25 (142.17–186.98) ^{*†}
Aldosterone (pg/mL)	150.05 (129.32–164.32)	159.62 (119.16–169.30) [†]	141.54 (118.63–154.83) [†]

The normal and elevated blood pressure groups were compared with the healthy control group, respectively, by Student's *t* test or the Mann-Whitney test ([§] Two-Sample T-test, [†] Mann Whitney U test/Wilcoxon Sum Rank test).

* $P < 0.05$ is considered statistically significant.

<https://doi.org/10.1371/journal.pone.0250815.t005>

Table 6. The renin-angiotensin system in subjects with and without elevated blood pressure.

Laboratory findings	Total	Normal blood pressure	Elevated blood pressure
	(median, IQR)	(median, IQR)	(median, IQR)
Adrenocorticotrophic hormone (pg/mL)	30.56 (20.99–40.54)	27.55 (21.12–39.56)	33.03 (19.42–40.89)
Renin (pg/mL)	6.01 (4.15–7.46)	6.35 (3.34–7.83)	5.86 (4.41–6.76)
Angiotensin α (pg/mL)	153.67 (129.17–175.98)	137.12 (123.63–161.67)	169.25 (142.17–186.98)*
Aldosterone (pg/mL)	142.11 (119.16–163.28)	159.62 (119.16–169.30)	141.54 (118.63–154.83)

Student's *t* test was used to compare the differences between normal and elevated blood pressure groups

**P* < 0.05 is considered statistically significant.

<https://doi.org/10.1371/journal.pone.0250815.t006>

protein, lactic dehydrogenase, and history of hypertension and diabetes were significantly associated with the clinical severity of COVID-19. In the multivariate analysis, the age, cTnI and history of hypertension and diabetes remained significant independent predictors (OR = 1.11, 95% CI: 1.07–1.16, *p* < 0.001; OR = 1.08, 95% CI: 1.01–1.15, *p* = 0.018; OR = 7.19, 95% CI: 2.55–20.31, *p* < 0.001; OR = 4.28, 95% CI: 1.41–12.97, *p* = 0.010; **Table 8**). The receiver operating characteristic curve of the four independent predictors and gender for clinical severity of COVID-19 is shown in **Fig 3A** (AUC: 0.932, sensitivity: 98.67%, specificity: 75.68%). The calibration indicated that the model was well-calibrated (**Fig 3B**).

Table 7. Clinical characteristics of severe and non-severe COVID-19 patients.

	Clinical Severity		Normal range
	Non-severe	Severe	
	(n = 111, 59.68%)	(n = 75, 40.32%)	
Age (y/o), Median (IQR)	42 (33–51)	66 (57–76)* [§]	-
Gender (n, %)			
Male	45 (40.54)	45 (60.00)* [£]	-
Female	66 (59.46)	30 (40.00)* [£]	-
Clinical categories (n, %)			
Elevated blood pressure	6 (5.41)	10 (13.33) [£]	-
Hypertension	15 (13.51)	20 (26.67)* [£]	-
Diabetes	7 (6.31)	21 (28.00)* [£]	-
Chronic lung diseases	7 (6.31)	10 (13.33) [£]	-
Chronic kidney diseases	2 (1.8)	2 (2.67) [#]	-
Gastrointestinal diseases	2 (1.8)	1 (1.33) [#]	-
Malignant tumor	2 (1.8)	0 (0)	-
Laboratory findings			
cTnI (pg/mL)	5.68 (4.62–6.45)	7.00 (5.78–27.00)* [†]	0–40.00
White blood cells ($\times 10^9$ cells/L)	5.07 (3.65–6.00)	5.98 (4.60–10.00)* [†]	3.50–9.50
Neutrophils ($\times 10^9$ cells/L)	2.67 (2.15–3.92)	3.85 (3.02–8.27)* [†]	1.80–6.30
Lymphocytes ($\times 10^9$ cells/L)	1.27 (0.96–1.73)	0.78 (0.48–1.29)* [†]	1.10–3.20
Monocytes ($\times 10^9$ cells/L)	0.42 (0.34–0.54)	0.44 (0.29–0.69) [†]	0.10–0.60
Procalcitonin (pg/mL)	36.00 (23.00–57.00)	67.50 (32.00–288.00)* [†]	0–100.00
C-reactive protein (mg/L)	6.20 (0.50–28.00)	48.55 (7.40–81.50)* [†]	0–10.00
Lactic dehydrogenase (U/L)	233.50 (187.50–292.00)	316.00 (235.00–454.00)* [†]	120–250

Student's *t* test, Mann-Whitney test, χ^2 test and Fisher's exact tests were used to compare the age, gender, and clinical category between the two groups ([§] Two-Sample T-test, [†] Mann Whitney U test/Wilcoxon Sum Rank test, [£] Pearson's chi-square test, [#] continuous correction Chi-square test).

**P* < 0.05 is considered statistically significant.

<https://doi.org/10.1371/journal.pone.0250815.t007>

Table 8. Univariate and multivariate analysis for clinical severity of COVID-19.

	Odds ratio	95% CI	P-value
Univariate analysis			
Age (years)	1.12	1.09–1.15	<0.001*
Male (%)	2.20	1.21–4.00	0.010*
cTnI (pg/mL)	1.13	1.05–1.22	0.002*
White blood cells ($\times 10^9$ cells/L)	1.39	1.13–1.70	0.002*
Neutrophils ($\times 10^9$ cells/L)	1.50	1.19–1.90	0.001*
Lymphocytes ($\times 10^9$ cells/L)	0.23	0.10–0.54	0.001*
Procalcitonin (pg/mL)	1.01	1.00–1.01	0.069
C-reactive protein (mg/L)	1.02	1.01–1.04	0.002*
Lactic dehydrogenase (U/L)	1.01	1.00–1.01	0.001*
Hypertension (%)	2.489	1.185–5.226	0.016*
Diabetes (%)	5.78	2.31–14.45	<0.001*
Multivariate analysis			
Age (years)	1.11	1.07–1.16	<0.001*
Male (%)	1.38	0.57–3.37	0.479
CTnI (pg/mL)	1.08	1.01–1.15	0.018*
Hypertension (%)	7.19	2.55–20.31	<0.001*
Diabetes (%)	4.28	1.41–12.97	0.010*

The logistic regression model was used to determine factors associated with the clinical severity of COVID-19 according to Table 7

*P < 0.05 is considered statistically significant.

<https://doi.org/10.1371/journal.pone.0250815.t008>




Fig 3. A. ROC curves of the age, cTnI, gender, and the presence of hypertension and diabetes for the identification of the severity of COVID-19. B. The calibration plot for the comparison of the predicted and actual probability. The X-axis and Y-axis represent the model-predicted and actual probability of MAE, respectively. The red line: perfect prediction. The black line: predictive performance of the model after bootstrapping (B = 1000 repetitions).

<https://doi.org/10.1371/journal.pone.0250815.g003>

Discussion

SARS-CoV-2 has been identified as a single-stranded enveloped 39 RNA virus belonging to the beta-coronavirus genus of the coronaviridae family [3]. These coronaviruses have a three-dimensional spike protein structure protein, which can closely bind the human ACE2 receptor. Therefore, the cells with ACE2 expression may act as target cells and be susceptible to SARS-CoV-2 infection [12]. ACE2 is a membrane-bound aminopeptidase with a vital role in the cardiovascular system [13, 14]. It is, therefore, reasonable to speculate that SARS-CoV-2 will act on the heart and blood vessels, with resultant changes in the cardiovascular system.

Serum cardiac troponin assays have been proposed as the recommended marker of cardiac injury in COVID-19 patients [15]. Huang and colleagues find that cTnI is increased substantially in 12.20% (5/41) Wuhan COVID-19 patients, in whom the diagnosis of the virus-related cardiac injury is made [8]. Another previous research also reported that patients with cardiac injury had higher levels of leukocyte counts, C-reactive protein, procalcitonin [16]. In this retrospective study, older patients with diabetes are more likely to suffer from cardiac injury. Our further analysis shows that the level of white blood cells, neutrophils, procalcitonin, C-reactive protein, lactate, and lactic dehydrogenase were positively associated with cardiac injury. Besides, the cardiac injury occurred mostly in severe patients. Consequently, we hypothesize that the severe type of COVID-19 characterized by acute inflammation response might be more prone to cardiac injury, especially in patients with preexisting cardiovascular disease. Chronic myocardial injury, acute nonischemic injury, and acute myocardial infarction have all been proposed as causes of cTnI elevation in COVID-19 patients [17]. One case study suggested that direct myopericardial involvement may be a complication of COVID-19 infection [18].

Understanding of the pathogenesis and complications of COVID-19 is still limited. Due to the lack of viral load quantification results in the literature, it is unclear whether the cardiac injury is directly related to viral load. The recent literature review has shown that although cTnI concentration is only marginally increased in all patients with COVID-19, (values above the 99th percentile upper reference limit in only 8–12% of positive patients), they are significantly increased in patients with severe disease [19]. Our study further suggests that cardiac injury is an independent risk factor for severe COVID-19 and in combination with age and other statistically significant comorbidities can be used to construct a logistic regression model of COVID-19 severity in hospitalized patients.

Sixteen patients without prior hypertension had a rise in blood pressure during hospitalization, and higher systolic blood pressure was observed in most of the patients. Except for lymphocytes and procalcitonin, no significant differences are found in patients with and without elevated blood pressure. This suggests that abnormal blood pressure may be caused independently of the inflammatory response. The RAS plays a critical role in the cardiovascular system, which includes a classical RAS axis (ACE-Ang II-AT1R pathway) and a non-classical RAS axis (ACE2-Ang 1-7-MasR-based pathway), counter-balancing role of the two axes regulates cardiovascular physiology and disease [20, 21]. ACE2 cleaves Ang II into the Ang 1-7, thus limiting substrate availability in the adverse ACE/Ang II/AT1 receptor axis [22, 23]. Keidar and colleagues found that ACE2 antihypertensive properties may be due to the degradation of angiotensin II [24]. In this study, the laboratory results of RAS show that Ang II level is elevated in the majority of patients without prior hypertension. Compared with normal blood pressure and healthy control groups, Ang II levels were significantly higher in elevated blood pressure groups. A possible mechanism may be the binding of SARS-CoV-2 to ACE2 thereby inhibiting degradation of angiotensin II leading to elevated blood pressure. Another hypothesis is that over activation of the RAS system promotes inflammatory response and cytokine storm, which stimulates the NADH/NADPH oxidase system and triggers cell contraction and

vasoconstriction, which then leads to COVID-19 related lung injury. Though the underlying mechanism remains to be elucidated, it is becoming evident that RAS plays a major role in hypertension and COVID-19 infection, as observed in our study. It has been noticed that recombinant human ACE2 is considered as a treatment for patients with COVID-19 (*ClinicalTrials.gov ID: NCT04287686*). This finding probably shades important implications for future treatment strategies. A recent long-term observational follow-up study of patients with COVID-19 reported nearly one-eighth of patients without previous renal dysfunction developed a reduction in glomerular filtration rate at follow-up. In addition, COVID-19 survivors suffer from relatively higher levels of depression, anxiety, and somatic symptoms (including fatigue or muscle weakness). Severe cases are more susceptible to the development of reduced pulmonary diffusion capacities [25]. Multiple above factors are capable of inducing hypertension in nonhypertensive patients. In addition, the median ages of these patients were 66.5 y/o. It seems that SARS-CoV-2 infection is just a trigger, and age plays a more important role.

On the other hand, sixteen patients with elevated blood pressure show significantly higher levels of cTnI than those normal blood pressure patients. Several studies have demonstrated Ang II direct or indirect effects on cardiomyocytes, some of which were related to pro-inflammatory and pro-hypertrophic responses [26]. Especially when the balance between the ACE and ACE2 was disrupted in COVID-19 patients, the increase in Ang II actions could lead to myocardial inflammation, oxidative stress, and myocyte apoptosis. This hypothesis explains why elevated blood pressure could occur in parallel with mild cardiac injury of COVID-19 patients.

Study strength and limitations

In the present study, we propose that hypertension is probably a sequela of SARS-CoV-2 infection. Although a number of studies of COVID-19 have been reported, there are few reports about the sequela of the disease likely due to lack of long-term clinical follow-up, which also applies to our present research. Next, it is difficult to analyze whether the blood pressure of COVID-19 patients with preexisting hypertension is further increased. Consequently, many patients could not be incorporated in the analysis because of the history of hypertension, which results in a relatively low sample size. Besides, the present study uncovered rising Ang II as one possible mechanism that might result in hypertension in COVID-19. However, due to a lack of detection about ACE2 levels and other components, therefore, we cannot gain a comprehensive view of virus-induced imbalance of the RAS pathway.

Conclusion

In summary, SARS-CoV-2 may impair cardiomyocytes by systemic acute inflammation response, and the cTnI is correlated with the severity of the infection. Accompanied by mild elevation in cTnI, spontaneous hypertension may occur in patients during hospitalization, and could become a sequela of SARS-CoV-2 infection, which may be associated with markedly elevated Ang II levels.

Acknowledgments

We gratefully acknowledge contributions from all enrolled patients and related medical staff.

Author Contributions

Conceptualization: Ganxiao Chen, Xun Li, Zuojiang Gong, Hao Xia, Yao Wang, Yan Huang, Hector Barajas-Martinez, Dan Hu.

Data curation: Ganxiao Chen, Xun Li, Zuojiang Gong, Yao Wang, Yan Huang, Dan Hu.

Formal analysis: Ganxiao Chen, Xun Li, Zuojiang Gong, Hao Xia, Xuefen Wang, Yan Huang.

Funding acquisition: Ganxiao Chen, Xun Li, Xuefen Wang.

Investigation: Ganxiao Chen, Xun Li.

Methodology: Ganxiao Chen, Xun Li, Hao Xia.

Project administration: Ganxiao Chen, Xun Li, Yao Wang, Xuefen Wang, Yan Huang, Hector Barajas-Martinez.

Resources: Ganxiao Chen, Hao Xia, Yao Wang, Xuefen Wang, Hector Barajas-Martinez.

Software: Ganxiao Chen, Xuefen Wang, Hector Barajas-Martinez, Dan Hu.

Supervision: Ganxiao Chen, Zuojiang Gong, Hector Barajas-Martinez, Dan Hu.

Validation: Ganxiao Chen, Zuojiang Gong, Hao Xia, Hector Barajas-Martinez.

Visualization: Ganxiao Chen, Zuojiang Gong, Yao Wang, Dan Hu.

Writing – original draft: Ganxiao Chen, Xun Li, Zuojiang Gong, Yao Wang, Yan Huang, Dan Hu.

Writing – review & editing: Ganxiao Chen, Xun Li, Zuojiang Gong, Hao Xia, Dan Hu.

References

1. Lu H, Stratton CW, and Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *J Med Virol.* (2020) 92:401–402. <https://doi.org/10.1002/jmv.25678> PMID: 31950516
2. Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis.* (2020) 91:264–266. <https://doi.org/10.1016/j.ijid.2020.01.009> PMID: 31953166
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.* (2020) 382:727–733. <https://doi.org/10.1056/NEJMoa2001017> PMID: 31978945
4. Brojakowska A, Narula J, Shimony R and Bander J. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week. *J Am Coll Cardiol.* (2020) 75:3085–3095. <https://doi.org/10.1016/j.jacc.2020.04.028> PMID: 32305401
5. Chen Y, Guo Y, Pan Y, and Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. *Biochem Biophys Res Commun.* (2020) 525(1):135–140. <https://doi.org/10.1016/j.bbrc.2020.02.071> PMID: 32081428
6. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ Res.* (2020) 126:1456–1474. <https://doi.org/10.1161/CIRCRESAHA.120.317015> PMID: 32264791
7. Keidar S, Kaplan M and Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1–7). *Cardiovasc Res.* (2007) 73:463–9. <https://doi.org/10.1016/j.cardiores.2006.09.006> PMID: 17049503
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) PMID: 31986264
9. Hu D, Liu K, Li BX, Hu ZH. Large Intra-cardiac Thrombus in a COVID-19 Patient Treated with Prolonged Extracorporeal Membrane Oxygenation Implantation. *Eur Heart J.* (2020) 41(32):3104–3105. <https://doi.org/10.1093/eurheartj/ehaa524> PMID: 32607534
10. National Health and Health Commission and State Administration of traditional Chinese medicine. Diagnosis and treatment of pneumonia caused by new coronavirus infection(Trial version 5[J/OL]). *Chinese J Integrated Traditional Western Medicine.* (2020) 40:136–8. <https://doi.org/10.7661/j.cjim.20200202.064>

11. Bonaca M, Scirica B, Sabatine M, Dalby A, Spinar J, Murphy SA, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. *J Am Coll Cardiol.* (2010) 55:2118–24. <https://doi.org/10.1016/j.jacc.2010.01.044> PMID: 20447535
12. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* (2020) 579:270–273. <https://doi.org/10.1038/s41586-020-2012-7> PMID: 32015507
13. Turner AJ, Hiscox JA and Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. *Trends Pharmacol Sci.* (2004) 25:291–4. <https://doi.org/10.1016/j.tips.2004.04.001> PMID: 15165741
14. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. The emerging role of ACE2 in physiology and disease. *J Pathol.* (2007) 212:1–11. <https://doi.org/10.1002/path.2162> PMID: 17464936
15. Venge P, Johnston N, Lindahl B and James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. *J Am Coll Cardiol.* (2009) 54:1165–72. <https://doi.org/10.1016/j.jacc.2009.05.051> PMID: 19761938
16. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol.* (2020) 5:802–810. <https://doi.org/10.1001/jamacardio.2020.0950> PMID: 32211816
17. Sandoval Y, Januzzi JL Jr. and Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. *J Am Coll Cardiol.* (2020) 76:1244–1258. <https://doi.org/10.1016/j.jacc.2020.06.068> PMID: 32652195
18. Inciardi RM, Lupi L, Zacccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* (2020) 5:819–824. <https://doi.org/10.1001/jamacardio.2020.1096> PMID: 32219357
19. Lippi G, Lavie CJ and Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. *Prog Cardiovasc Dis.* (2020) 63:390–391. <https://doi.org/10.1016/j.pcad.2020.03.001> PMID: 32169400
20. Paz Ocaranza M, Riquelme JA, Garcia L, Jalil JE, Chiong M, Santos RAS, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. *Nat Rev Cardiol.* (2020) 17:116–129. <https://doi.org/10.1038/s41569-019-0244-8> PMID: 31427727
21. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH and Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. *Circ Res.* (2015) 116:960–75. <https://doi.org/10.1161/CIRCRESAHA.116.303587> PMID: 25767283
22. Wang K, Gheblawi M and Oudit GY. Angiotensin Converting Enzyme 2: A Double-Edged Sword. *Circulation.* (2020) 142:426–428. <https://doi.org/10.1161/CIRCULATIONAHA.120.047049> PMID: 32213097
23. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA and Diz DI. Update on the Angiotensin converting enzyme 2-Angiotensin (1–7)-MAS receptor axis: fetal programming, sex differences, and intracellular pathways. *Front Endocrinol (Lausanne).* (2014) 4:201. <https://doi.org/10.3389/fendo.2013.00201> PMID: 24409169
24. Keidar S, Strizevsky A, Raz A and Gamliel-Lazarovich A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. *Nephrol Dial Transplant.* (2007) 22:597–601. <https://doi.org/10.1093/ndt/gfl632> PMID: 17095582
25. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet.* (2021) 397:220–232. [https://doi.org/10.1016/S0140-6736\(20\)32656-8](https://doi.org/10.1016/S0140-6736(20)32656-8) PMID: 33428867
26. Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, et al. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. *Physiol Rev.* (2018) 98:1627–1738. <https://doi.org/10.1152/physrev.00038.2017> PMID: 29873596